SG11201810137UA - Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof - Google Patents

Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

Info

Publication number
SG11201810137UA
SG11201810137UA SG11201810137UA SG11201810137UA SG11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA
Authority
SG
Singapore
Prior art keywords
pro
international
pct
diseases
human neutrophil
Prior art date
Application number
SG11201810137UA
Inventor
Christian Ludin
Manfred Keller
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of SG11201810137UA publication Critical patent/SG11201810137UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization MD 1101/110 111010101111101011111 0 0111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/207117 Al 07 December 2017 (07.12.2017) WIP0 I PCT (51) International Patent Classification: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, A61K 8/64 (2006.01) A61K 9/00 (2006.01) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61K 38/12 (2006.01) CO7K 7/64 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/EP2017/025156 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 31 May 2017 (31.05.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 16020210.7 31 May 2016 (31.05.2016) EP Published: (71) Applicant: POLYPHOR AG [CH/CH]; Hegenheimermat- — with international search report (Art. 21(3)) tweg 125, 4123 Allschwil (CH). (72) Inventors: LUDIN, Christian; Im Drissel 24, 4104 Ober- wil (CH). KELLER, Manfred; Neunkirchner Str. 60, 81379 Mfinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, _ — HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = Title: BETA-HAIRPIN PEPTIDOMIMETIC WITH ELASTASE INHIBITORY ACTIVITY AND AEROSOL DOSAGE FOR- = (54) = MS THEREOF = = Fig. 1 (57) : The present invention relates to pharmaceuti- cal aerosols comprising a 0-hairpin peptidomimetic of formu- la cyclo(-OctG-Glu-Thr-Ala-Ser-lle-Pro-Pro-Gln-Lys-Tyr- D Pro- = = Pro-), or a pharmaceutically acceptable salt thereof, having in- hibitory activity against human neutrophil elastase. It further re- lates to solid or liquid pharmaceutical compositions and kits for = * **** preparing and administering such aerosols. The invention can be v** -1- used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fi- brosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic — = • 1 obstructive pulmonary disease (COPD), or infections, or diseases, — 1-1 5 w or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity. Thus, the invention further re- IN lates to a pharmaceutical composition or a pharmaceutical aerosol 1-1 comprising the active compound cyclo(-OctG-Glu-Thr-Ala-Ser- 1-1 IN lle-Pro-Pro-Gln-Lys-Tyr- D Pro-Pro-), or any pharmaceutically ac- © ceptable salt thereof, for use in a method for the prevention, man- e , ' agement or treatment of diseases or conditions of the lungs being IN mediated by or resulting from human neutrophil elastase activity 1-1 0 ei Inhalation dosing in a subject. O
SG11201810137UA 2016-05-31 2017-05-31 Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof SG11201810137UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16020210 2016-05-31
PCT/EP2017/025156 WO2017207117A1 (en) 2016-05-31 2017-05-31 Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

Publications (1)

Publication Number Publication Date
SG11201810137UA true SG11201810137UA (en) 2018-12-28

Family

ID=56108445

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201810138XA SG11201810138XA (en) 2016-05-31 2017-05-31 Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
SG11201810137UA SG11201810137UA (en) 2016-05-31 2017-05-31 Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
SG10202113280XA SG10202113280XA (en) 2016-05-31 2017-05-31 Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201810138XA SG11201810138XA (en) 2016-05-31 2017-05-31 Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202113280XA SG10202113280XA (en) 2016-05-31 2017-05-31 Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

Country Status (26)

Country Link
US (3) US11235024B2 (en)
EP (2) EP3463281B1 (en)
JP (4) JP7286319B6 (en)
KR (2) KR102511284B1 (en)
CN (3) CN116159024A (en)
AU (2) AU2017273507B2 (en)
BR (2) BR112018074551B1 (en)
CA (2) CA3024522A1 (en)
CL (2) CL2018003390A1 (en)
DK (2) DK3463281T3 (en)
EA (2) EA039603B1 (en)
ES (2) ES2927948T3 (en)
HR (2) HRP20221185T1 (en)
HU (2) HUE060393T2 (en)
IL (2) IL263114B2 (en)
LT (2) LT3463280T (en)
MA (2) MA45168A (en)
MX (2) MX2018014752A (en)
PH (2) PH12018502521A1 (en)
PL (2) PL3463281T3 (en)
PT (2) PT3463280T (en)
RS (2) RS63639B1 (en)
SG (3) SG11201810138XA (en)
UA (2) UA125899C2 (en)
WO (2) WO2017207118A1 (en)
ZA (2) ZA201807772B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263114B2 (en) * 2016-05-31 2023-12-01 Spexis Ag Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
IL294959A (en) * 2020-01-30 2022-09-01 Vertex Pharma Methods of treatment for alpha-1 antitrypsin deficiency
AU2021383950A1 (en) * 2020-11-23 2023-06-22 Spexis Ag Compositions of a beta-hairpin peptidomimetic and aerosol dosage forms thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270290A1 (en) * 1996-11-01 1998-05-14 Xoma Corporation Therapeutic uses of bpi protein products in cystic fibrosis patients
WO2006079019A2 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
NZ556747A (en) 2005-02-17 2009-09-25 Polyphor Ltd Template-fixed beta-hairpin peptidomimetics with protease inhibitory acitivity
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
MX2008010172A (en) 2006-02-09 2009-09-07 Pari Gmbh Pulmonary delivery of alpha-i proteinase inhibitor.
MX2008010222A (en) * 2006-02-10 2008-10-17 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy.
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
EP1927373B1 (en) * 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
ES2532667T3 (en) 2011-09-12 2015-03-30 Meiji Seika Pharma Co., Ltd. Aqueous compositions containing arbekacin
WO2015096672A1 (en) 2013-12-23 2015-07-02 石家庄铁道大学 Detection device
JP6431486B2 (en) 2013-12-26 2018-11-28 株式会社カネカ Solar cell IV measuring method, solar cell IV measuring apparatus, solar cell manufacturing method, solar cell module manufacturing method, and solar cell module
WO2015096873A1 (en) * 2013-12-27 2015-07-02 Polyphor Ag Beta-hairpin peptidomimetics as selective elastase inhibitors
EA034910B1 (en) 2013-12-27 2020-04-06 Полифор Аг Beta-hairpin peptidomimetics as selective elastase inhibitors
IL263114B2 (en) * 2016-05-31 2023-12-01 Spexis Ag Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

Also Published As

Publication number Publication date
KR20190015309A (en) 2019-02-13
EP3463280B1 (en) 2022-07-06
EP3463281A1 (en) 2019-04-10
JP2019523763A (en) 2019-08-29
IL263112B1 (en) 2023-06-01
MX2018014425A (en) 2019-03-28
JP2023017793A (en) 2023-02-07
MA45168A (en) 2019-04-10
EA201892819A1 (en) 2019-05-31
ZA201807772B (en) 2022-10-26
US11235023B2 (en) 2022-02-01
HRP20221194T1 (en) 2022-12-09
ZA201807773B (en) 2022-07-27
JP7286319B2 (en) 2023-06-05
PL3463280T3 (en) 2022-11-07
US20200230202A1 (en) 2020-07-23
WO2017207117A1 (en) 2017-12-07
BR112018074532A2 (en) 2019-03-19
PT3463281T (en) 2022-10-07
EP3463281B1 (en) 2022-07-06
US20200230203A1 (en) 2020-07-23
BR112018074532B1 (en) 2022-02-08
KR20190011750A (en) 2019-02-07
WO2017207118A1 (en) 2017-12-07
JP2022078013A (en) 2022-05-24
HUE060119T2 (en) 2023-02-28
CA3024522A1 (en) 2017-12-07
CN116159024A (en) 2023-05-26
IL263112B2 (en) 2023-10-01
PT3463280T (en) 2022-10-07
MA45167A (en) 2019-04-10
AU2017273507A1 (en) 2018-12-13
EA201892818A1 (en) 2019-05-31
CL2018003391A1 (en) 2019-05-03
SG11201810138XA (en) 2018-12-28
US11844823B2 (en) 2023-12-19
EP3463280A1 (en) 2019-04-10
LT3463280T (en) 2022-09-26
IL263114B2 (en) 2023-12-01
EA039603B1 (en) 2022-02-16
BR112018074551B1 (en) 2022-02-08
IL263112A (en) 2018-12-31
US11235024B2 (en) 2022-02-01
CN109195580A (en) 2019-01-11
IL263114A (en) 2018-12-31
IL263114B1 (en) 2023-08-01
DK3463281T3 (en) 2022-09-26
LT3463281T (en) 2022-09-26
AU2017273507B2 (en) 2022-03-17
HUE060393T2 (en) 2023-02-28
RS63622B1 (en) 2022-10-31
PH12018502521A1 (en) 2019-10-21
SG10202113280XA (en) 2021-12-30
PL3463281T3 (en) 2022-11-07
CN109310613A (en) 2019-02-05
KR102511284B1 (en) 2023-03-16
AU2017273508B2 (en) 2022-07-28
DK3463280T3 (en) 2022-09-26
CA3024521C (en) 2023-06-20
CL2018003390A1 (en) 2019-05-03
UA125899C2 (en) 2022-07-06
KR102480800B1 (en) 2022-12-22
CA3024521A1 (en) 2017-12-07
ES2928050T3 (en) 2022-11-15
AU2017273508A1 (en) 2018-12-13
BR112018074551A2 (en) 2019-03-06
JP7286319B6 (en) 2023-06-16
MX2018014752A (en) 2019-04-25
ES2927948T3 (en) 2022-11-14
RS63639B1 (en) 2022-10-31
HRP20221185T1 (en) 2022-12-09
JP2019523222A (en) 2019-08-22
PH12018502522A1 (en) 2019-10-21
UA125900C2 (en) 2022-07-06
US20220023379A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
SG11201907034PA (en) Methods of treating influenza
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201900471VA (en) Combination therapy for copd
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201807963WA (en) Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus
SG11201809702SA (en) Benzenesulfonamide compounds and their use as therapeutic agents
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201810137UA (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
SG11201907217RA (en) Pharmaceutical combinations for treating cancer
SG11201901070YA (en) Formulations for oral administration of active agents
SG11201808650QA (en) Methods of treating ocular conditions
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201809494VA (en) Pharmaceutical composition comprising eteplirsen